Baxter Phillips
Operationeel Directeur bij LOBE SCIENCES LTD.
Vermogen: 10 880 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Philip Young | M | 66 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 7 jaar |
Sherden Timmins | M | - |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | 9 jaar |
Frederick Sancilio | M | 74 | - | |
Sandra Dosdall | F | 55 | - | |
Michael Petter | M | - | 3 jaar | |
Andrew Clark | M | - |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Jonathan Milner | M | 59 |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | 11 jaar |
Maghsoud Dariani | M | - | 4 jaar | |
Mathew Lee | M | 40 | 1 jaar | |
Sigurdur Martinsson | M | - |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David O'Flynn | M | - | - | |
Jonathan Gilbert | M | 52 | 2 jaar | |
M. Scott Salka | M | 62 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 jaar |
Matthew M. Loar | M | 61 | 2 jaar | |
Wendy Johnson | F | 72 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 5 jaar |
Kelley A. Wendt | F | 49 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 jaar |
David E. Bosher | M | 70 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 jaar |
John M. Barberich | M | 66 | 3 jaar | |
Bobby Sandage | M | 70 | 5 jaar | |
Alexander Gaidamaka | M | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
Anthony Smithyman | M | 74 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 jaar |
Enda Kenny | M | - | 2 jaar | |
Julian P. Kirk | M | 50 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 jaar |
Florian Schönharting | M | 55 | - | |
Jeremy Curnock-Cook | M | 75 | 3 jaar | |
Thadd M. Vargas | M | 58 |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | - |
Christian Hansen | M | 58 | - | |
Christopher Barry Wood | M | 78 | - | |
Brian Zasitko | M | 44 | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Ierland | 9 | 31.03% |
Verenigde Staten | 9 | 31.03% |
Canada | 8 | 27.59% |
Verenigd Koninkrijk | 4 | 13.79% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Baxter Phillips
- Persoonlijk netwerk